Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6982067 | 0.88 | DGAT1 (0.58) | DGAT1BRD4ALDH1A1HPGD | |
| SCHEMBL6982954 | 0.82 | DGAT1 (0.58) | DGAT1KDM4EALDH1A1POLBHTT | |
| SCHEMBL15050223 | 0.82 | DGAT1 (0.47) | DGAT1BRD4ALDH1A1 | |
| SCHEMBL16661146 | 0.82 | DGAT1 (0.66) | DGAT1BRD4PDE10A | |
| SCHEMBL17810246 | 0.81 | DGAT1 (0.62) | DGAT1BRD4PDE10A | |
| SCHEMBL12963688 | 0.80 | DGAT1 (0.50) | DGAT1PDE10A | |
| SCHEMBL67976 | 0.80 | DGAT1 (0.50) | DGAT1BRD4PDE10A | |
| SCHEMBL27338948 | 0.80 | DGAT1 (0.54) | DGAT1BRD4PDE10A | |
| SCHEMBL23123637 | 0.78 | DGAT1 (0.46) | DGAT1BRD4PDE10A | |
| SCHEMBL616813 | 0.78 | DGAT1 (0.48) | DGAT1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | DGAT1 3367/4885BRD4 182/4885KDM4E 3041/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | DGAT1 2240/4885BRD4 192/4885KDM4E 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.